CDKN2A and cancer: Additionally, trametinib is also recommended by BRAF and MAP2K1 alterations, as well as new molecular evidence, such as G6PD (mutation and high overexpression), CDKN2A (deletion and underexpression) and due to the genetic dependency of MAP2K1 in BRAF-mutant cancer cell lines (Figure 2).